GVAG
AUPH icon

Great Valley Advisor Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Great Valley Advisor Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,400
Closed -$52.1K – 781
2024
Q1 		$52.1K Buy
+10,400
New +$70.5K ﹤0.01% 738

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Great Valley Advisor Group's AUPH Position: Q2 2024 in Review

Great Valley Advisor Group sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2024, closing a stake of 10,400 shares — an estimated $52.1K sold.

Great Valley Advisor Group first reported a position in AUPH in Q1 2024 and held it in 1 quarter. The position peaked at $52.1K in Q1 2024. 171 funds tracked by Wall St. Rank hold AUPH as of Q2 2024.

  • Great Valley Advisor Group reported no remaining Aurinia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Great Valley Advisor Group sold 10,400 Aurinia Pharmaceuticals shares in Q2 2024, an estimated $52.1K.
  • Great Valley Advisor Group first reported a position in Aurinia Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Great Valley Advisor Group's Aurinia Pharmaceuticals position peaked at $52.1K in Q1 2024.
  • 171 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2024.

Based on Great Valley Advisor Group's 13F filing for Q2 2024, filed 16 Jul 2024.